BioHarvest Sciences plans to dual-list its ordinary shares on Nasdaq and the Tel Aviv Stock Exchange, with registration covering all 22,667,842 outstanding common shares. The company expects TASE trading to start September 8, 2026, saying the move should broaden access to its shares and deepen ties with Israel’s Investment community.

Key Highlights

  • Up to 4,516,021 common shares are available for future issuance under BioHarvest Sciences’ Equity Incentive Plan.
  • Investor warrants cover 610,742 additional common shares issuable upon exercise.
  • TASE trading is expected to begin on September 8, 2026, under the English symbol BHST.

BIOHARVEST SCIENCES INC. (NASDAQ: BHST) plans to add trading on the Tel Aviv Stock Exchange, with the proposed dual listing covering all 22,667,842 outstanding common shares. TASE trading is expected to begin September 8, 2026.

Equity Plan and Warrants Expand Registration Scope

That pool includes 2,564,876 outstanding Options and 269,521 restricted share units, while 1,681,624 shares remain available for future grants.

TASE Listing Targets Israeli Investor Access

BioHarvest says the additional venue is intended to broaden access to its shares and strengthen its connection with the Israeli investment community. The common shares remain listed on the Nasdaq Capital Market, while the TASE line is expected to use the English symbol BHST and an alternative Hebrew symbol. CEO Dr. Zaki Rakib described the dual-listing plan as a natural step for an Israeli-founded company with global ambitions. He linked it to a new growth phase built on the Botanical Synthesis platform and its commercial opportunities.